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ABSTRACT
Purpose: To evaluate the clinical utility, diagnostic yield and rationale of integrating 
microarray analysis in the clinical diagnosis of hematological malignancies in comparison 
with classical chromosome karyotyping/fluorescence in situ hybridization (FISH).
Methods: G-banded chromosome analysis, FISH and microarray studies using 
customized CGH and CGH+SNP designs were performed on 27 samples from patients 
with hematological malignancies. A comprehensive comparison of the results obtained 
by three methods was conducted to evaluate benefits and limitations of these 
techniques for clinical diagnosis.
Results: Overall, 89.7% of chromosomal abnormalities identified by karyotyping/
FISH studies were also detectable by microarray. Among 183 acquired copy number 
alterations (CNAs) identified by microarray, 94 were additional findings revealed in 14 
cases (52%), and at least 30% of CNAs were in genomic regions of diagnostic/prognostic 
significance. Approximately 30% of novel alterations detected by microarray were >20 
Mb in size. Balanced abnormalities were not detected by microarray; however, of the 19 
apparently “balanced” rearrangements, 55% (6/11) of recurrent and 13% (1/8) of non-
recurrent translocations had alterations at the breakpoints discovered by microarray.
Conclusion: Microarray technology enables accurate, cost-effective and time-
efficient whole-genome analysis at a resolution significantly higher than that of 
conventional karyotyping and FISH. Array-CGH showed advantage in identification 
of cryptic imbalances and detection of clonal aberrations in population of non-dividing 
cancer cells and samples with poor chromosome morphology. The integration of 
microarray analysis into the cytogenetic diagnosis of hematologic malignancies has 
the potential to improve patient management by providing clinicians with additional 
disease specific and potentially clinically actionable genomic alterations.
INTRODUCTION
Classical cytogenetic analysis (G-banding) plays 
a critical role in the diagnosis, prognosis and treatment 
planning of hematologic malignancies [1–16], and enables 
the detection of large genomic alterations, including 
aneusomies, balanced and unbalanced chromosomal 
rearrangements of at least 10–20 Mb in size, and 
Oncotarget18846www.impactjournals.com/oncotarget
mosaicism. However, the necessity for dividing cells, 
sometimes poor chromosome morphology, and the 
relatively low-resolution of G-banding are limiting factors 
for a complete and accurate chromosome study.
Fluorescence in situ hybridization (FISH) has proven 
invaluable as an ancillary technique for the identification of 
clinically significant chromosomal aberrations, as FISH can 
be performed on metaphase or non-dividing interphase cells, 
and can detect genomic abnormalities with a resolution from 
150 to 900 kb, depending on the probe size. In hematologic 
malignancies, FISH enables the rapid detection of: 1) fusion 
genes amenable to targeted therapy (e.g., PML-RARA, 
ABL1-BCR); 2) other recurrent cytogenetic abnormalities 
of diagnostic or prognostic importance that may be present 
in quiescent cells, including both chromosomal rearrange-
ments and copy number abnormalities; 3) submicroscopic 
copy number changes of clinical significance, such as 
deletions involving TP53 and ATM; 4) relatively low-level 
mosaicism for clonal aberrations by evaluation of a large 
population of interphase cells; and 5) may facilitate the 
characterization of complex chromosome rearrangements 
identified by G-banded analysis. Most laboratories use a 
set of commercially available, single-locus probes to detect 
genetic changes in specific, targeted genomic regions that are 
diagnostic or prognostic for a certain type of hematologic 
malignancy, such as FISH panels for acute myeloid leukemia 
(AML) or acute lymphoblastic leukemia (ALL). Despite 
numerous advantages, FISH does not provide genome-wide 
analyses and must be targeted to selected genomic regions 
believed to be of interest in a given case. FISH may yield 
false negative results in cases where genomic imbalances 
are smaller than the size of a FISH probe or chromosomal 
rearrangements are complex; or false positive results when 
two fluorescent signals co-localize due to viewing a three-
dimensional nucleus in two dimensions.
The advent of high-resolution genome arrays, 
including comparative genomic hybridization (CGH) 
and single nucleotide polymorphism (SNP), has enabled 
the detection of submicroscopic copy number variations 
of clinical significance, in addition to the majority of 
abnormalities identifiable by G-banding and FISH 
[17–22]. Microarray analysis eliminates the need for 
dividing cells and can be performed on direct (uncultured) 
specimens to provide a more accurate assessment of 
abnormalities and tumor burden. SNP arrays also can 
detect genomic regions with loss of heterozygosity 
(LOH), a clinically significant aberration associated with 
hematologic and other malignancies [17, 18, 22–24]. 
Array-CGH cannot detect balanced rearrangements or 
genomic imbalances present in less than 10–20% of cells. 
Furthermore, the precise physical location of genomic 
gains cannot be determined by microarray analysis and 
requires G-banding or FISH for further characterization.
In the past decade, advances in genomic technologies, 
such as high-throughput sequencing and whole genome 
microarray studies have provided a wealth of insights 
into mechanisms of cancer development and evolution. 
Molecular pathways have been identified that drive 
cancer cell transformation and progression, convey tumor 
clinical behavior and response to therapy. As a result, 
an international working group reported a number of 
recommendations giving special attention to the detection 
of disease-associated cytogenetic and molecular defects, 
prognostic genetic markers, and novel targeted therapeutic 
options for hematologic malignancies [4–9].
The 2008 WHO classification of hematologic 
malignancies incorporates cytogenetic abnormalities that are 
mainly well-recognized using classical cytogenetic studies 
with limited categories requiring FISH studies or mutational 
analyses [1]. To date, for example, genetic lesions in at least 21 
genes have been implicated in pathogenesis of myelodysplastic 
syndrome (MDS) [4]. The International Prognositic Scoring 
System (IPSS) and the National Comprehensive Cancer 
Network (NCCN; www.nccn.org) guidelines recognize five 
prognostic categories in MDS that include evaluation for 
inv(3)/t(3)/del(3q), del(5q), −7/del(7q), +8, del(12p), +19, and 
del(20q). In addition, FISH analyses for RUNX1-RUNX1T1, 
CBFB-MYH11, and PML-RARA may be necessary to exclude 
AML. Further genetic screening for submicroscopic deletions 
and duplications, along with point mutations is recommended 
in patients with familial MDS/AML. Although large genomic 
alterations are readily detectable by classical cytogenetic 
techniques, the low-resolution of G-banding is insufficient 
to detect submicroscopic aberrations. Thus, the burden falls 
upon FISH, and the continued expansion of FISH panels is 
infeasible due to prolonged turn-around time, cost, and the 
inability to target all genomic regions of clinical interest. 
Therefore, it is critical for cytogenetics laboratories to adopt 
technology that will provide clinicians with results as quickly 
and efficiently as possible.
To date, multiple studies have shown the value 
of microarray analysis in the diagnosis of hematologic 
malignancies [17–24]. Here we present the results of a 
comprehensive comparison between classical chromosome 
karyotyping (G-banding), FISH, and microarray studies, 
and demonstrate the benefits, limitations and rationale 
of microarray analysis in the clinical diagnosis of 
hematologic malignancies.
RESULTS
Twenty-seven specimens were analyzed for DNA 
copy number variations (CNVs) using either the CGH 
or CGH+SNP microarray design (GEO accession no. 
GSE66960, http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=svsnkiyatnmbnyz&acc=GSE66960) and 
compared with results of clinical G-banding and/or FISH 
studies (Supplementary Table S1 and S2).
For example, we compared G-banding, FISH 
(MDS panel), and array-CGH results in a patient with 
a provisional diagnosis of MDS (Figure 1). Array-
CGH detected specific MDS-associated aberrations [del 
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(7q), del(20q), and +8], additional genomic changes 
consistent with MDS evolving into AML, and complex 
chromosome alterations suggestive of chromothripsis 
(Figure 2). In contrast to the results of G-banding and 
FISH studies, microarray analysis provided definitive 
genomic alterations of diagnostic and prognostic 
significance and eliminated the need for additional FISH 
studies.
Figure 1: Comparison of G-banding, FISH, and array-CGH results from a patient (CP-13) with Myelodysplastic 
Syndrome. G-banded karyotype. Karyotype at the 400-band resolution showing an abnormal clone with five abnormalities (boxed): 
deletion of the long arm of chromosome 7; trisomy 8; monosomies 9 and 20; 1 to 4 marker chromosomes; and 4 to 27 double minutes. 
According to WHO classification (2008), 50% of MDS cases have gross cytogenetic aberrations at diagnosis including deletion 5q, deletion 
7q or monosomy 7, trisomy 8, and deletion 20q. Approximately 30% of MDS patients will acquire additional genomic aberrations and 
develop acute myeloid leukemia (AML). To date, mutations, fusion transcripts, deletions, duplications and amplifications in at least 21 
genes are associated with transformation of MDS into AML. Classical cytogenetic analysis enables whole-genome evaluation of malignant 
clones; however, cryptic chromosomal abnormalities will be missed due to the low-resolution of this technique. MDS FISH panel. The 
MDS FISH panel using single-locus probes consists of three hybridization experiments to detect four common genomic imbalances 
[del(5q), del(7q), trisomy 8, and del(20q)] in interphase nuclei. FISH is a targeted approach to identify abnormalities in specific regions 
of the genome. Therefore, the extent and complexity of chromosomal deletion/duplication, as well as aberrations involving the other 
chromosomal regions will remain undetected. In MDS patients with a high-risk for transformation into AML, additional FISH studies or 
an AML FISH panel are frequently requested. Array-CGH. High-resolution whole-genome profiling by microarray identified multiple 
genomic imbalances. Microarray probes are arranged according to their physical map locations on each chromosome from the distal p-arm 
(on the left) to the distal q-arm (on the right). Chromosomes are plotted in a horizontal fashion and are listed at the bottom. An average 
logarithmic ratio (log2) is displayed for all oligonucleotide probes. Probes with a log2 ratio clustered around zero indicate DNA segments 
with normal copy numbers. A positive log2 ratio (above zero) indicates a gain (extra copy) of the chromosomal region, while intervals with 
a negative log2 ratio (below zero) represent loss of DNA copy number. Deletion 7q and trisomy 8 are concordant (black arrows) with the 
results of G-banding and FISH analyses, while array-CGH revealed a loss of most of chromosomes 9 and 20 (blue arrows). Microarray 
analysis also detected multiple 9p, 9q, and 20q segments with a gain or no change in DNA copy number, consistent with a complex 
rearrangement (partially concordant results with G-banded studies). In addition, array-CGH revealed abnormalities missed by G-banding 
or FISH (red arrows), including: mosaic monosomies 11 and 16; a deletion in the short arm of chromosome 12 (12p13.2 region); mosaic 
loss of one X chromosome, and a deletion of the long arm of the chromosome X (Supplementary Table S2). Genes implicated in MDS and 
AML transformation is indicated by black dots along the array-CGH plot.
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Completely concordant results between 
G-banding/FISH and microarray analyses
Findings of G-banding/FISH and microarray 
analyses were concordant in 5 of 27 cases (18.5%) (CP-4, 
CP-10, CP-12, CP-16, and CP-22). CP-4 had an abnormal 
karyotype containing multiple small acentric fragments 
or double minutes (dmin). In CP-4, FISH analysis was 
positive for MYC gene amplification, and microarray 
analysis further characterized the 8q24 amplified region 
(Figure 3a–3c). Cases CP-10 (Figure 4a) and CP-16 had 
aneusomies as the sole abnormality, all of which were 
detected by both G-banding/FISH and microarray analysis. 
CP-22 had a normal karyotype by G-banding analysis; 
however, two abnormal cell lines with heterozygous (nuc 
ish (D13S319x1, LAMPx2)) and homozygous (nuc ish 
(D13S319x0, LAMP x2)) 13q14 deletions were detected 
by FISH analysis (Supplementary Table S2). Microarray 
analysis revealed two distinct regions of copy number 
loss suggestive of heterozygous (13q13.3-q21.2) and 
homozygous (13q14.2-q14.3) deletions (Supplementary 
Table S2).
CP-12 had a questionable del(5)(q34q35) in all 20 
G-banded cells. FISH analysis was negative for deletions 
Figure 2: Focused evaluation of aberrations detected by G-banding, FISH, and array-CGH from a patient 
(CP-13) with myelodysplastic syndrome. a. Aberrant chromosomes determined by G-banding karyotyping. b. The results of 
MDS FISH panel studies. c. A chromosome view of array-CGH analysis. Regions with a DNA copy number loss are indicated in 
red, and intervals with gains are highlighted in blue. d. A magnified view of the rearranged chromosomal regions. On the left, an 
idiogram with a red box showing a region of interest. On the right, array-CGH plot depicting rearrangement. There was complete 
concordance among all methodologies for deletion 7q and trisomy 8. For monosomies 9 and 20, G-banding was partially concordant 
with array-CGH analysis. Alternating regions of gain and loss spanning chromosome 9 and amplification of a proximal region of 
20q most likely account for the marker chromosomes and double minutes identified by G-banding. The MDS FISH panel does not 
target chromosome 9 (NA, FISH is not applicable), and because a single probe for 20q is utilized, the amplified 20q region was not 
detected. Lastly, microarray identified a deletion, spanning the short arm of chromosome 12, that included the ETV6 gene, which has 
been implicated in MDS transformation to AML.
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at the D5S23 (5p15.2), EGR1 (5q31), and CSF1R (5q33-
34) loci, and microarray was normal.
Partially concordant results between G-banding/
FISH and microarray analyses
In 14 cases (CP-1, CP-7, CP-8, CP-11, CP-
13, CP-15, CP-17, CP-18, CP-20, CP-23, CP24, CP-
25, K-1 and K-3), microarray results were consistent 
with previous findings by classical chromosome and/
or FISH studies. Moreover, additional alterations 
(Supplementary Table S2) were detected in each case, 
including: partial monosomy for 4p and 8p (CP-24; 
Figure 4b); low level mosaicism for hyperdiploidy 
(CP-25; Figure 4c); homozygous CDKN2A and 
CDKN2B deletions (CP-17 and CP-20, Figure 5a–5d); 
heterozygous deletions of PAX5 (CP-18 and CP-20, 
Figure 5e–5f); an extra derivative chromosome der(21)
t(12;21) in a patient with a normal karyotype (CP-18, 
Figure 6); amplification of the 8q24 region containing 
the MYC gene represented by homogeneously 
staining regions (hsr) (CP-23, Figure 3d–3f); and 
submicroscopic imbalances at the translocation or 
inversion breakpoints (K-1, CP-7, K-3, Figure 7). CP-1 
had an extra chromosome 21 in 2 of 20 metaphase cells, 
but interphase FISH analysis using D21S259, D21S341, 
and D21S342 (21q22.13-q22.2) probes was negative for 
an extra chromosome 21. Microarray analysis did not 
detect trisomy 21, but did reveal a 419-kb heterozygous 
deletion of the 17q11.2 chromosome region that 
included the NF1 gene (Supplementary Table S2).
Discordant results between G-banding/FISH and 
microarray analyses
Five of 27 cases (CP-2, CP-5, CP-6, CP-9 diagnosed 
with AML, and CP-14 diagnosed with CML) with 
balanced translocations as the sole main abnormality 
according to G-banding and/or FISH analysis had normal 
microarray results as expected.
Figure 3: G-banding, FISH, and array-CGH analysis in two cases with 8q24 amplification. a. A metaphase spread from 
CP-4 showing double minutes (arrows) detected by G-banded classical cytogenetic analysis. b. Interphase FISH analysis demonstrated 8q24 
amplification using the MYC break-apart probe (Vysis). c. A magnified view of the array-CGH plot. Each dot represents an oligonucleotide 
probe. The black dots indicate probes without change in copy number and red dots indicate a single copy loss. Chromosomal gain 
suggestive of one, two or multiple extra copies is indicated by blue, green and orange dots, respectively. Abnormal regions with at least 
five consecutive probes deviating from the normal log2 ratio are highlighted in red (deletions) or in blue (duplications, triplications, or 
amplifications). Array-CGH analysis demonstrated amplification (orange dots) of 8q24.13-q24.21, which includes the TRIB1, MYC and 
PVT1 genes (blue shaded area). d. A partial karyotype from CP-23 showing the der(14) and der(22) chromosomes, both with homogenously 
staining regions (hsr). e. Partial karyotype of the same metaphase cell subjected to FISH analysis utilizing the IGH (green)/MYC (red) dual 
fusion translocation probe set. The red signal hybridized to the hsr region on the der(14) chromosome, consistent with MYC amplification. 
f. Array-CGH analysis demonstrated gain of whole chromosome 8-specific probes (blue dots), consistent with trisomy 8, and amplification 
of 8q24.21 (orange dots), spanning the MYC gene. FISH analysis for MYC amplification was initiated due to the microarray findings, and 
aided in the interpretation of the classical karyotype.
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Detection rate for numerical and structural 
chromosome abnormalities
In our study, 121 abnormalities were detected by 
G-banding and/or FISH analyses and compared to microarray 
findings (Table 1). These included 78 (14 monosomies, 30 
trisomies, 3 tetrasomies, 18 deletions, 1 duplication, and 
12 derivative chromosomes) unbalanced abnormalities 
characterized by G-banding, 24 aberrations of unknown 
origin, and 19 balanced rearrangements. Microarray results 
were consistent with the results of G-banding for (62 + 8)
(concordant + partially concordant) of 78 abnormalities 
(89.7%). This includes 13 monosomies (5 concordant + 8 
partially concordant, interpreted as monosomies by classical 
cytogenetic studies), 27 trisomies, 3 tetrasomies, 14 deletions, 
1 duplication, and 12 derivative chromosomes (Table 1). 
Interestingly, whole chromosome monosomies had been 
detected by microarray analysis in only 5 of 14 instances 
(36%), while in 8 of 14 cases (57%), the DNA segments from 
the missing chromosome were present in parts comprising 
derivative, marker, or double minute chromosomes.
Eight of 78 (10.3%) abnormalities (Table 1), 
including 1 monosomy, 3 trisomies, and 4 deletions, were 
not detected by microarray analysis. In CP-19, monosomy 
18 and trisomy for chromosomes 1, 13, and 15 were 
not detected by microarray analysis whereas G-banding 
detected +X, +1, +8, +13, +15, –18. In this case, karyotype 
analysis was performed on unstimulated bone marrow 
cultures, in contrast to microarray studies that used DNA 
from an uncultured specimen. In order to evaluate the level 
of mosaicism in cultured cells, we completed additional 
FISH studies using the X centromere-specific probe on 
interphase cells from the patient’s 24-hour culture. FISH 
analysis showed trisomy X in 16 of 200 cells examined 
(8%) from a 24-hour culture, while in a 72-hour culture, 
additional chromosome X was observed in 10 of 20 cells 
(50%). Therefore, the level of abnormal cells with trisomy 
1, 13, 15 and monosomy 18 in vivo is likely to be below 
the detection range (~10%) for microarray analysis.
Four deletions—del(11)(q23q24)[19] (CP-3), 
del(2)(q31q37)[2/20] (CP-13), del(5)(q12q33)[1] (CP-
13), and del(3)(q26.2q27)[4/20] (CP-19)—were not 
detected by microarray analysis. These deletions might 
be not detected by microarray due to a low level of 
abnormal clones in uncultured samples, or alternatively, 
the chromosomal regions which appear to be deleted 
might be inserted into another genomic region. Thus, 
in CP-3 (Figure 8c–8d), the deletion identified by 
G-banding was not confirmed by FISH or microarray 
studies.
Figure 4: Large chromosomal aberrations detected by aCGH analysis. a. Whole genome microarray plot from CP-10. An 
increased log2 average was detected for all chromosome 8-specific probes, indicating low-level mosaicism (~7% based on FISH results) for 
trisomy 8, consistent with results of G-banded karyotyping and FISH studies. b. The array-CGH plot from CP-24 shows gain of all probes 
specific for chromosomes 3, 4, 5, 7, 9, 11, 15, 18, 19, and 21 (blue-shaded areas), and loss of 8p-specific probes (red-shaded). Please note 
the average log2 = 0.95, indicative of tetrasomy for chromosomes 15 and 21. Microarray and G-banding results were discordant for two 
segments: distal 4p and 8q (arrows), suggestive of mosaic monosomy 4p in addition to trisomy 4 and an 8p deletion versus monosomy 
8. Retrospective review of G-banded cells revealed one metaphase cell with poor chromosome morphology, showing 8q attached to 4p, 
accounting for the discrepancy. Suboptimal chromosome morphology and an insufficient number of metaphase cells precluded classical 
cytogenetic recognition of this abnormality associated with clonal evolution, whereas it was detected by array-CGH. c. The microarray plot 
from CP-25, showing gain of chromosomes 3, 5, 9, 11, 15, 19, and 21 and loss of the X chromosome. FISH analysis for 11q- and 5q-specific 
probes showed an extra signal in ~7% of cells.
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Additional genomic alterations revealed by 
microarray
Microarray analysis detected 183 CNVs including 
losses in 94 regions, gains in 84 regions, and DNA 
amplification in five genomic loci (Supplementary 
Table S2). In addition, nine LOH segments ranging in size 
from 33.6 to 197.5 Mb, were detected in two of 11 cases 
studied by CGH + SNP design.
In 14 cases (14/27, 52%) (CP-4, CP-7, CP-8, CP-
11, CP-13, CP-15, CP-17, CP-18, CP-19, CP-20, CP-
23, CP-25, K-1, and K-3), microarray analysis revealed 
94 additional genomic alterations. At least 65 additional 
genomic alterations revealed by microarray were in the 
regions previously characterized by classical chromosome 
karyotyping and/or FISH (Supplementary Table S2), 20 of 
which (30.7%, Table 1) had diagnostic and/or prognostic 
significance in patients with hematologic malignancies. 
For example, homozygous CDKN2A and CDKN2B 
deletions in two patients with B-cell acute lymphoblastic 
leukemia (B-ALL), which confers a poor prognosis in 
adult B-ALL [27], and heterozygous PAX5 deletions in two 
B-ALL patients (Figure 5) were not detected by traditional 
chromosome studies, but were revealed by aCGH analysis. 
Both homozygous CDKN2A and CDKN2B deletions and 
heterozygous PAX5 deletions are frequent abnormalities in 
pediatric and adult B-ALL [15, 28, 29], and are valuable 
markers for disease monitoring.
Among additional microarray findings, there 
were 61 cryptic alterations (61/94, 65%) that are 
below 10 Mb in size (Figures 2, 3, 5, 7), and 28 DNA 
segments (28/94, 30%) larger than 20 Mb, including 
10 instances of whole chromosome aneuploidy. In 
CP-25 (Figure 4c), microarray analysis revealed an 
abnormal clone with trisomy for chromosomes 3, 5, 9, 
11, 15, 19, and 21 and monosomy X, while classical 
cytogenetic study showed a 45,X,-X karyotype in 
20 cells. Similarly, gains in the 12p13.2-p13.3 and 
21p11.2-q22.12 chromosome regions, which correspond 
to an extra derivative chromosome, der(21)t(12;21)
(p13;q22), due to ETV6/RUNX1 gene rearrangement 
(Table 2, Figure 6), were identified, in CP-18, with 
normal karyotype. This highlights the advantage of 
evaluation of uncultured samples by microarray, as 
populations of malignant cells may not divide in vitro, 
under the same conditions as normal cells, and could 
therefore be missed by classical cytogenetic analysis.
Among our cases, microarray analysis detected 
genomic imbalances present as low as in 7–10% of 
abnormal cells.
Figure 5: Array-CGH analysis detects cryptic aberrations of diagnostic significance. a. A partial karyotype from CP-17, 
showing a deletion of the short arm of one chromosome 9 (arrow), and an apparently normal chromosome 9 homolog. b. Array-CGH 
analysis revealed a 4.2-Mb homozygous deletion spanning CDKN2A and CDKN2B, indicating that this deletion is present on what appears 
to be a normal chromosome 9. c. Array-CGH analysis of CP-20 revealed a 164-kb homozygous deletion spanning CDKN2A and CDKN2B. 
Aberrations of chromosomes 9 were not detected by G-banded karyotype. d. A magnified view of the deleted region (dashed double arrow) 
spanning the CDKN2A and CDKN2B genes from CP-20. The deleted segment spans a part of the LSI p16 FISH probe (Vysis; orange bar), 
precluding detection of this deletion by FISH analysis. e, f. Intragenic deletions of the PAX5 gene in two patients with B-ALL (CP-18 and 
CP-20), detected by microarray analysis.
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Figure 6: Detection of a supernumerary der(21)t(12;21) chromosome by array-CGH analysis in a patient with an 
apparently normal karyotype by classical cytogenetic analysis. Array-CGH plots for chromosome 12 a. and 21 b. revealing 
gains of 12p13.33–13.2 and 21p11-q22.12. c, d. Magnified views showing breakpoint sites (red arrows) located in intron 5 of the ETV6 
gene (c), and intron 1 of the RUNX1 gene (d). These results are consistent with an ETV6/RUNX1 rearrangement and an extra der(21)t(12;21)
(p13;q22) chromosome, also detected by FISH.
Figure 7: Alterations at the breakpoint sites detected by microarray analysis in apparently balanced translocations 
detected by classical cytogenetic analysis. a. Array-CGH analysis in K-1 demonstrating an 18 kb deletion spanning part of intron 1a 
(arrow) of the RUNX1T1 gene, a common breakpoint site associated with the RUNX1/RUNX1T1 rearrangement. G-banded chromosome 
analysis revealed what appeared to be a balanced t(8;21)(q22;q22) translocation. b. Array-CGH analysis of CP-7 demonstrating a 155 kb 
deletion spanning exon 6 of the CBFB gene and 15 other genes downstream of CBFB. The proximal breakpoint of this deletion is located 
in intron 5 of the CBFB gene. G-banded analysis revealed what appeared to be a balanced inv(16)(p13q22). c. Microarray analysis of K-3 
showed a 108 kb deletion spanning intron 1a of the MECOM gene in what was an apparently balanced t(3;7)(q26;q22) translocation.
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Table 1: Summary of microarray results compared to classical cytogenetics (G-banding) and FISH 
results for 27 hematologic malignancy specimens
Aberration Number of 
Abnormalities 
detected by 
G-banding/
FISH
Microarray results
Concordant Partially 
concordant
Discordant 
(not 
detected)
Additional findings 
(not detected by 
G-banding/FISH)
Overall Clini cally 
signifi cant&
Unbalanced, 
characterized by 
G- banding/FISH
Whole 
chromosome 
monosomy
14 5/14 (36%) 8/14 (57%)^ 1 3 –
Whole 
chromosome 
trisomy
30 27/30 (87%) – 3 5 5
Whole 
chromosome 
tetrasomy
3 3/3 (100%) – – 2 –
Deletions 18 14/18 (78%) – 4 36 13
Duplications 1 1/1 (100%) – – 16 –
Derivative 
chromosomes
12 12/12 (100%) – – 3 2
Total 78 62/78 (79.5%)
8/78 
(10.2%)
8/78 
(10.3%)
65 20/65 
(30.7%)
Unbalanced, 
undetermined
Derivative 
chromosomes 
with chromatin 
of unknown 
origin
13 – 7 – 5 1
Marker/dmin 
chromosomes
10 1 – – 9* –
Uncertain 
deletion
1 1 – –
Total 24 1 7 1 14 1
Balanced rearrangements@ 
(breakpoint sites)
19 (34) 2 (3) – – 6 (9) 5/6
^losses of chromosomal material have been detected by microarray, however some chromosomal segments were present on 
the derivative, marker or dmin chromosomes. Detailed info is given in the Supplementary Table S2.
&losses or gains encompassing genes that were reported in the literature to be involved in the pathogenesis or associated 
with patient’s disease prognosis.
* microarray detected gains of genomic segments, elucidating chromosome origin of marker and dmin 
chromosomes.
@see Table 2 for genomic loci and sizes.
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Table 2: Genomic alterations at the breakpoints of cytogenetically balanced rearrangements
Patient Diag-
nosis
Rear-
range-
ments
Abnormal 
G-banded 
cells
Abnormal 
cells by 
FISH
Rear-
rangement 
type
Alteration(s) 
at 
break point 
site(s)
Location(s) Size Gene at 
break-
point
CP-2 AML t(15;17)(q24;q21)
[16/20] [200/237] Recurrent – – – –
CP-3 AML t(9;11)(p22;q23)
[19/20] Not 
performed
Recurrent – – – –
CP-5 AML t(4;12)(q12;p13)
[17/20] [223] Recurrent – – – –
CP-7 AML inv(16)(p13q22)
[15/20] [173/218] Recurrent Loss 16q22.1 155 kb CBFB, 
intron 5
CP-9 AML t(16;16)(p13;q22)
[7/20] Not 
performed
Recurrent – – – –
CP-14 CML t(9;22)(q34; q11.2)
Not 
performed
[203/240] Recurrent – – – –
CP-15 CML
t(9;22)(q34; 
q11.2), + 
der(22)
t(9;22)
[20] [224] Recurrent Loss 
Gain 
Loss 
Gain
9q34.11-q34.12  
9q34.12-q34.3 
22q11.23 
22q11.1-q11.23  
1.9 Mb 
7.5 Mb 
1.6 Mb 
7.6 Mb
ABL1, 
intron 1 
BCR, 
major 
break point
CP-18 B- ALL
t(12;21)
(p13;q22), 
+ der(21)
t(12;21)
[0/20] [210/222] Recurrent Gain 
Gain
12p13.33-p13.2  
21p11.2-q22.12 
11.8 Mb 
27 Mb
ETV6, 
intron 5 
RUNX1, 
intron 1
CP-19 B- ALL
t(4;11)
(q21;q23)
[17/20] [236/242] Recurrent Gain 11q23.3-q25  16.6 Mb MLL, 
intron 8
K-1 AML t(8;21)(q22;q22)
[20] Not 
performed
Recurrent Loss 8q21.3 18 kb RUNX1T1, 
intron1a
K-3 AML t(3;7)(q26;q22)
[20] Not 
performed
Recurrent Loss 
Loss
3q26.2 
7q22.1  
108 kb 
82 kb
MECOM, 
intron 1a
CP-6 AML
t(11;20)
(p15; 
q11.2)
[18/20] NA Non-
recurrent
– – – –
CP-6 AML t(3;5)(q21;q31)
[2/20] NA Non-
recurrent
– – – –
CP-6 AML t(12;17)(p10;q10)
[2/20] NA Non-
recurrent
– – – –
CP-15 CML t(5;6)(q13;q23)
[20] NA Non-
recurrent
– – – –
CP-19 B- ALL
t(2;15)
(q31;q22)
[4/20] NA Non-
recurrent
– – – –
CP-19 B- ALL
t(5;6)
(q35;p21)
[4/20] NA Non-
recurrent
– – – –
(Continued )
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A total of 19 apparently balanced rearrangements, 
including 18 translocations and one inversion, were 
identified by G-banding and/or FISH analysis (Table 2). 
Eleven rearrangements were recurrent abnormalities 
associated with oncogenic fusion transcripts, whereas 
the remaining eight were identified as non-recurrent. 
Balanced rearrangements are not detectable by microarray 
techniques; however, microarray detected genomic 
imbalances in six of 11 (55%) recurrent cytogenetically 
balanced abnormalities (Figure 7), and in one of 8 (13%) 
non-recurrent apparently balanced translocations.
Combined G-banding and microarray results 
help to characterize complex rearrangements
In addition to the 78 abnormalities already 
described, 24 unbalanced rearrangements, including 13 
derivative chromosomes with chromatin of undetermined 
origin, 10 marker chromosomes and/or double minutes, 
and 1 questionable deletion, were identified by G-banding 
analysis (Table 1). Of the 13 derivative chromosomes 
with chromatin of undetermined origin from five cases 
(CP-8, CP-21, CP-23, K-1, and K-3), five rearrangements 
Figure 8: Combined results of G-banding, FISH, and microarray studies enable more accurate characterization of 
chromosomal aberrations in patients with hematological malignancies. a. Partial karyotype of CP-21, showing add(4)(q35) 
and del(13)(q12q22), and b. array-CGH analysis showing a 1-Mb deletion of the 13q14.2-q14.3 chromosome region. The discrepancy 
between the 13q deletion size, along with the absence of genomic region gains, prompted a retrospective evaluation of the G-banded 
karyotype. Based on combined data, it has been concluded that the additional material on 4q is derived from 13q, and the rearrangement can 
be interpreted as a complex unbalanced translocation between chromosomes 4q and 13q, resulting in an interstitial 13q14 deletion. c. Partial 
karyotype of CP-3, showing the t(9;11)(p22;q23) translocation (arrows), in addition to a del(11)(q23q24) involving the other chromosome 
11 (arrow head). d. An MLL break-a-part probe (11q23) was utilized to confirm the t(9;11) translocation and to confirm the 11q23-q24 
deletion involving the other chromosome 11. The metaphase cell demonstrates a single red and single green signal, consistent with a split 
MLL probe and the t(9;11)(p22;q23) translocation. However, the presence of a fused yellow signal indicates that the 11q23-q24 region was 
inserted elsewhere in the genome and was not truly deleted. This was consistent with microarray analysis, as no deletions were detected in 
the 11q23-q24 region. e. Partial karyotype of CP-8, showing additional chromatin material on the short arm of chromosome 21. f. Array-
CGH plot for chromosome 16, showing a loss for 16q and mosaic loss for 16p. g. FISH with 21q and 16p-specific probes confirmed the 
presence of 16p on the derivative chromosome 21.
Patient Diag-
nosis
Rear-
range-
ments
Abnormal 
G-banded 
cells
Abnormal 
cells by 
FISH
Rear-
rangement 
type
Alteration(s) 
at 
break point 
site(s)
Location(s) Size Gene at 
break-
point
CP-19 B- ALL
t(16;17)
(p13.3;q12)
[17/20] NA Non-
recurrent
Loss 
Loss
16p13.3-p11.2 
17p13.3-p11.2   
30.3 Mb 
20.7 Mb
SRCAP
K-3 AML t(2;5)(p13;q33) [20] NA
Non-
recurrent – – – –
AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; B-ALL, B-cell acute lymphoblastic leukemia; 
NA, not applicable.
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Figure 9: Regions of homozygosity detected by CGH+SNP array analysis point toward the nature of chromosomal 
rearrangements and mechanisms of clonal evolution. a. Array-CGH plot of chromosome 6, showing a two-copy gain for all 6p-specific 
probes (blue shaded area). An idiogram of chromosome 6 is on the left. The SNP plot, showing a loss of heterozygosity (LOH) for the long arm of 
chromosome 6 (light blue shaded area), indicated by two tracks of homozygous alleles (AA and BB), is on the right. Isochromosome 6p is detected 
by an increased log2 ratio, consistent with four copies of 6p (array-CGH analysis) and three tracks of homozygous and heterozygous alleles detected 
by SNP analysis (AAAA, AABB, and BBBB). b. Proposed mechanism of clonal evolution. Mitotic nondisjunction resulting in two copies each of 
homologous chromosomes. Further mitotic aberrations resulting from genomic instability include uniparental isodisomy (identical copies of two 
chromosomes) and an isodicentric 6p chromosome (i.e., one composed of two copies of the short arm). c. Idiogram of chromosome 11 on the left, 
accompanied by CGH and SNP results on the right. Two apparently normal chromosomes 11 were detected by classical chromosome analysis and 
array-CGH plot, consistent with chromosome 11 disomy. LOH for the short arm of chromosome 11 is indicated by two tracks of homozygous 
alleles detected by SNP analysis (AA and BB). d. Proposed mechanism of clonal evolution. Deletion of the short arm of chromosome 11, followed 
by replication of the short arm of the homologous chromosome 11, resulting in identical copies of 11p (LOH).
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Figure 10: SNP-containing microarrays are essential to differentiate clones with hyperdiploidy from a doubled 
hypodiploid population. a. Idiogram of chromosome 2 on the left, accompanied by CGH+SNP results on the right. Array-CGH analysis 
reveals a duplication (arrow) and triplication (double arrow) of the short arm of chromosome 2. Whole chromosome LOH is demonstrated 
by homozygous allele tracks (AA and BB; AAA and BBB; AAAA and BBBB). b. Proposed mechanism of clonal evolution. The initial 
aberration is monosomy 2, followed by mitotic nondisjunction and intrachromosomal recombination, producing extra fragments of 2p. 
The presence of LOH for the entire chromosome 2 indicates that numerical aberration is a primary event, while structural abnormalities 
are secondary changes in clonal evolution. c. Idiogram of chromosome 13 on the left, accompanied by CGH+SNP results on the right. 
Array-CGH analysis reveals trisomy 13 by an increased log2 ratio, and SNP array detected two homozygous allele tracks (AAA and BBB), 
indicating all three copies of chromosome 13 are identical. d. Proposed mechanism of clonal evolution. The initial aberration is monosomy 
13, followed by mitotic nondisjunction, resulting in whole chromosome LOH and gain of chromosome 13. Karyotypes with gains of 
multiple chromosomes are commonly interpreted as hyperdiploid; however, the presence of LOH regions for multiple chromosomes 
strongly indicates a hypodiploid nature of the rearrangement, thus differentiating true hyperdiploidy from doubled low-diploidy or near-
haploid clones and affecting prognostic significance.
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could be further characterized on the basis of additional 
microarray studies. In CP-21, a microarray finding of a 
1.03-Mb deletion within 13q14 and inconsistency with 
the reported karyotype prompted a retrospective review 
of the classical chromosome analysis and enabled 
precise characterization of the complex chromosomal 
rearrangement. The abnormalities add(4)(q35) and 
del(13)(q12q22) were reinterpreted as der(13)t(4;13)
(q35;q14)del(13)(q14.2q14.3) (Figure 8a–8b). In CP-8, 
additional chromatin on 21p was determined to originate 
from 16p (Figure 8e–8f), and in CP-23, homogeneously 
staining regions hsr(14)(p11.2) and hsr(22)(p11.2) were 
determined to be composed of 8q24 (Figure 3d–3e) and 
2p, respectively.
In cases with marker chromosomes and/or double 
minutes, microarray analysis provides the precise 
physical locations of amplified genomic regions, which 
can be further studied by FISH analysis, if necessary. For 
example, CP-13 had 1~4 marker chromosomes and 4~27 
double minutes by G-banding (Figure 2). Microarray 
analysis detected multiple regions on chromosome 
9 which appeared to be duplicated, triplicated, or 
amplified, as well as an amplified pericentromeric 
20q11.2 chromosome region. The marker chromosomes 
and double minutes in this case are most likely to 
be derived from chromosome 9 and the 20q11.2 
chromosome region, as no additional gains were detected 
by microarray analysis.
CGH + SNP design has advantage in detection of 
acquired LOH regions
A total of 11 cases (CP-1, CP-3, CP-4, CP-6, CP-
11, CP-14, CP-15, CP-16, CP-17, CP-19, and CP-23) 
were evaluated by CGH+SNP microarray. In two cases 
(CP-15 and CP-23), we detected acquired copy number 
neutral abnormalities - loss of heterozygosity (LOH) and 
LOH associated with gains of chromosomal segments 
(Supplementary Table S2). In CP-15, trisomy X was 
associated with LOH, which suggests clonal evolution 
stemming from the loss of one X chromosome, followed 
by duplication of the remaining chromosome X twice. 
In CP-23, LOH was detected on chromosomes 2, 3, 6q, 
11p, 13, 17, and 22 (Figures 9 and 10). Detection of 
LOH regions provided additional information toward the 
mechanism of clonal evolution.
DISCUSSION
Detection of malignant clones in hematologic 
specimens historically has involved the study of G-banded 
chromosomes, which provides low-resolution evaluation 
of the whole-genome. Complemented with locus-
specific FISH probes often used in panels, these studies 
remain the gold standard for detection of abnormal 
clones in hematologic malignancies [1]. However, the 
low resolution, the subjective nature of G-banding 
analysis, the need for dividing cells, the number of 
metaphase cells studied, and the limited number of 
FISH studies that can be performed on any given case, 
are considerable disadvantages when compared to high-
resolution molecular-based techniques. In addition, the 
labor-intensive specimen processing and time-consuming 
demands of chromosome and FISH analysis continue to 
mount with an increasing volume of specimens.
High-resolution whole-genome arrays which detect 
copy number changes, mosaicism, and LOH (SNP-array), 
have revolutionized the field of clinical cytogenetics. To 
date, microarray analysis is recommended as the first-
tier test in clinical diagnosis of patients with congenital 
anomalies, intellectual disability and in prenatal diagnosis 
of fetuses with abnormal ultrasound findings [30–31]. 
Microarray analysis allows chromosome evaluation at a 
significantly higher resolution than standard karyotype 
analysis, enabling detection of genomic imbalances 
throughout the whole genome in a single assay. The aims 
of our study were to evaluate the clinical utility, diagnostic 
yield and various technical aspects of microarray analysis 
in patients with hematologic malignancies.
Our group and others [17–24], have clearly 
demonstrated that approximately 85–90% of unbalanced 
clonal aberrations found by classical karyotypes are 
detectable by microarray analysis. G-banding analysis 
is beneficial in the detection of balanced chromosome 
alterations (translocations and inversions), examination 
of aberrant chromosomes and complex chromosomal 
rearrangements, and identification of abnormalities in 
related or unrelated malignant clones.
In 52% of our cases, array-CGH reveals additional 
genomic imbalances not seen by karyotype or FISH 
[17–24]. These imbalances comprised common alterations 
associated with specific hematologic malignancies, 
including deletions in the regions of CDKN2A, CDKN2B, 
PAX5, NF1, ETV1, ETV6, EZH2; amplifications of MYC 
and KIT; and alterations in other regions of the genome 
known to have diagnostic, prognostic, or treatment-related 
significance [27–29, 32–36]. Many clinically significant 
alterations are cryptic and variable in size, and may remain 
undiagnosed even by FISH studies with locus-specific 
probes. In our study, 65% of genomic regions uncovered 
by array-CGH were alterations less than 10 Mb in size. As 
shown in case CP-20 (Figure 5), a 164-kb homozygous 
deletion involving CDKN2A and CDKN2B spans only a 
part of the 190-kb LSI p16 probe, therefore, the remaining 
part of the probe will produce hybridization signals on both 
homologous chromosomes, yielding a false negative result.
Microarray analysis has greater analytical sensitivity 
to detect cryptic rearrangements that are below the 
resolution of karyotype or FISH analyses; however, it also 
adds value to reveal clonal abnormalities in a population 
of non-dividing cells. In our study, ~30% of novel 
alterations detected by microarray analysis were larger 
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than 20 Mb, but were missed by G-banding due to poor 
chromosome morphology or a lack of abnormal clones 
among the population of dividing cells. In patients with 
hematologic malignancies, specimens comprise a mixture 
of neoplastic and normal cells. Regardless of the technique 
used, the goal of classical and molecular cytogenetic 
testing in hematologic cancers is to find a clone of 
genetically abnormal cells among the total population of 
cells studied. An abnormal clone is defined by classical 
chromosome analysis as a population composed of at least 
two metaphase cells of 20 studied with the same structural 
aberration, thus G-banding analysis has the ability to 
identify 10% mosaicism. FISH studies may detect as low 
as 3–10% of abnormal cells, depending on the number of 
interphase nuclei examined and the probe used. Among 
our samples, alterations of at least 1 Mb in size detected by 
FISH in 8–15% of cells were also revealed by microarray 
studies. Evaluation of clonal abnormalities in populations 
of non-dividing cells can also be achieved by FISH 
analysis on interphase cells; however, prior knowledge of 
regions of possible interest is required for targeted FISH 
assays. In addition, FISH assesses abnormalities at a single 
genomic locus and, in some cases, may yield inconclusive 
or borderline results. In contrast to FISH, microarray 
analysis utilizes data from multiple oligonucleotide 
probes and does not require pre-existing knowledge of 
possible regions of interest, adding power to reveal low-
level mosaicism and cryptic alterations through the entire 
genome. In addition, direct testing of DNA extracted from 
uncultured specimens or after enrichment of the neoplastic 
cells rapidly provides objective data when compared to 
traditional G-banding analysis. Bypassing the need for 
dividing cells gives a more accurate assessment of in vivo 
aberrations and tumor burden, and eliminates the potential 
for in vitro culture selection. Moreover, it provides precise 
breakpoint locations and gene content of the affected 
regions.
Collective data indicate that ~40–70% [17–24] 
of cancer samples have acquired genomic imbalances. 
Our comprehensive analysis of the affected regions 
showed that ~30% of these alterations contain genes 
directly implicated in oncogenesis along with prognostic 
significance [27–29, 32–36], and ~45–50% of CNVs 
were found in patients with complex karyotypes which 
is consistent with global genomic instability in cancer 
cells. Interestingly, tumor suppressor genes known to be 
involved in DNA repair are commonly observed among 
the deleted chromosomal segments.
Microarrays enhance our ability to characterize 
derivative chromosomes with additional chromatin 
of unknown origin, genomic losses in hypodiploid 
clones, complex structural rearrangements, and marker 
chromosomes/double minutes when performed in parallel 
with classical cytogenetic analysis. In patient CP-23, we 
observed a highly abnormal karyotype which included 
homogenously staining regions (hsr) on chromosomes 14 
and 22 (Figure 3d–3f). Homogenously staining regions 
and double minutes are cytogenetic hallmarks of oncogene 
amplification in which amplified chromosomal regions can 
reach a few kilobases in size that contain a single gene, 
or encompass a hybrid DNA sequence composed of one 
or more genomic regions containing multiple genes [37]. 
Microarray analysis revealed MYC amplification that 
localized to the hsr on chromosome 14 by subsequent 
FISH analysis. In such cases, microarray analysis is 
the most efficient approach to identify amplified genes. 
Similarly, in CP-4 with AML, FISH analysis identified 
the composition of double minutes as amplification 
of the 8q24 chromosome region containing MYC, while 
the region of amplification was further characterized 
by microarray as a 4.45 Mb segment encompassing the 
TRIB1, MYC and PVT1 genes (Figure 3a–3c). Importantly, 
previous studies showed that TRIB1, not MYC, is the 
most likely amplified target gene in a subtype of AML/
MDS [36]. This highlights the benefit of incorporating 
microarray analysis into the clinical setting, which would 
provide high-resolution analysis and precise gene content 
identification for proper diagnosis and a potential targeted 
therapy of hematologic malignancies.
Although microarrays have advantages, they will 
never completely replace the traditional cytogenetic 
testing methodologies. Microarrays cannot provide 
chromosomal structural composition of complex 
aberrations without concurrent G-banding and/or FISH 
studies. In our study, about 10% of cases require analysis 
by all the three methodologies to enhance interpretation 
(Figure 8). Importantly, microarray analysis cannot detect 
truly balanced rearrangements that are often the primary 
oncogenic aberration in hematologic malignancies [38–
39]. However, in many instances, apparently balanced 
rearrangements identified by G-banding/FISH are 
unbalanced at the molecular level. Among our samples, 
55% of recurrent balanced rearrangements had cryptic 
copy number alterations at the breakpoints. The custom 
microarray design used in our study has ample coverage 
within the known recurrent translocation breakpoints, which 
may enhance detection of imbalances at the fusion gene or 
its reciprocal loci. Although the clinical significance has yet 
to be determined, the detection of copy number changes 
at breakpoint sites may herald the presence of a specific 
rearrangement and facilitate targeted FISH testing.
Despite the large success of genomic arrays in the 
constitutional setting, the transition into the oncology 
world has proceeded slowly. As stated by Hagenkord 
and Chang in 2009 [40], “array-based karyotyping is 
now on the verge of bursting into clinical oncology, ” 
yet six years later, G-banding and FISH remain the sole 
testing methodologies for hematologic malignancies in 
most cytogenetics laboratories. Microarray processing 
is significantly automated compared to classical 
karyotyping, which would reduce manual labor costs 
in the cytogenetics laboratory. Substantial amounts of 
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clinically relevant data have been presented in recent 
years that support the integration of microarray analysis 
into the diagnosis of hematologic malignancies [17–24, 
28]. Furthermore, technical guidelines and standards for 
diagnosis of neoplastic disorders by microarrays were 
developed by the American College of Medical Genetics 
and Genomics [41]. Based on collective evidence, results 
of microarray analysis are valuable in the diagnosis and 
cytogenetic risk assessment in oncologic specimens. 
Therefore, incorporation of microarray testing into the 
routine clinical diagnosis of hematologic malignancies 
at the time of diagnosis and relapse, in conjunction with 
classical karyotyping, could be very beneficial. Microarray 
testing can be particularly useful as a replacement for 
FISH assays for evaluation of bone marrow samples 
for multiple genomic gains and losses, such as MDS 
and CLL FISH panels, as long as there are sufficient 
numbers of neoplastic cells or they are enriched in some 
way; for detection of cryptic alterations that are beyond 
the resolution of FISH analysis; for risk assessment by 
genomic profiling, such as deletions involving the IKZF1, 
ETV6, PAX5, RB1, EBF1 genes in ALL patients [28, 29]; 
in samples with normal karyotype or culture failure; in 
cases with suspected gene amplification of unknown 
origin. With most hematologic diseases, timely diagnosis 
and management are critical; therefore, microarray testing 
would be beneficial and cost-effective in the clinical 
oncology setting, as this technology has the potential 
to impact clinical management, limit additional testing 
at different stages of disease, and improve treatment 
outcome.
MATERIALS AND METHODS
Clinical samples
This study was approved by the Institutional 
Review Board (IRB) at the University of Pittsburgh 
(PR009100456). A total of 25 specimens (17 bone marrow 
aspirates, 7 peripheral bloods, 1 lymph node) and two 
myeloblast cell lines Kasumi-1 (K-1) and Kasumi-3 (K-
3) [25–26] (ATCC repository (www.atcc.org) CRL-2724, 
CRL-2725), with clonal chromosomal abnormalities 
detected on G-banding and/or FISH analysis, or normal 
karyotypes were selected for microarray analysis 
(Supplementary Tables S1 and S2). The specimens 
included 11 acute myeloid leukemias (AML); 4 myelody-
splastic syndromes (MDS); 4 B-cell acute lymphocytic 
leukemias (B-ALL); 3 chronic lymphocytic leukemias 
(CLL); 2 chronic myeloid leukemias (CML); 2 plasma cell 
myelomas (PCM); and 1 polycythemia vera (PV). Clonal 
chromosomal abnormalities detected by G-banding and/or 
FISH analysis included whole chromosome aneusomies, 
unbalanced rearrangements, deletions, duplications, 
chromatin material of undetermined origin, marker 
chromosomes, double minutes, and apparently balanced 
rearrangements.
 G-banding and FISH analyses
Conventional G-banded chromosome analysis and/
or FISH analyses were performed on 25 clinical samples 
at the Pittsburgh Cytogenetic Laboratory. A minimum of 20 
metaphase cells [except CP-18 (15 cells), CP-19 (17 cells), 
CP-22 (18 cells), and CP-23 (15 cells)] were analyzed from 
24 and/or 48-hour harvests of unstimulated bone marrow 
aspirate, peripheral blood, and lymph node cell cultures. 
In addition, four of the specimens (CP-19, CP-23, CP-24, 
and CP25) were also analyzed from 72-hour phorbol-12-
myristate-13-acetate (PMA) stimulated cell cultures. Two 
peripheral blood specimens (CP-21 and CP-22) were only 
analyzed from 72-hour PMA-stimulated cells cultures. 
FISH studies were primarily performed on interphase 
cells, derived from 24-hour harvests of unstimulated cell 
cultures using Oncology-Hematology Vysis DNA probes 
(Abbott Laboratories, Des Plaines, IL) according to 
manufacturer protocol. FISH analysis and image capture 
was performed using Isis FISH Imaging System v5.3 
software (MetaSystems, North Royalton, OH).
Custom microarray design
To assist in the clinical diagnosis of hematological 
malignancies, we developed a custom genome-wide 
oligonucleotide microarray using Agilent 4x180K CGH 
and CGH+SNP designs (Agilent Inc. Santa Clara, CA). 
The target gene set composed of 898 genes known to be 
involved in carcinogenesis was derived from The Cancer 
Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/
tcga/tcgaDownload.jsp) and The Cancer Gene Census 
(COSMIC; http://cancer.sanger.ac.uk/cancergenome/
projects/census/) databases, and a comprehensive 
literature review. To achieve enhanced coverage for the 
898 targeted genes, we selected ~42,000 gene-specific 
probes with an average of one probe per 0.5–1 kb or at 
least 10 probes per gene. In addition, we included ~2,000 
probes mapped within 28 breakpoint “hot spot” intervals 
associated with recurrent balanced rearrangements, with 
an average spacing of one probe per 300–500 bp. The 
remaining probes (~136,000) for the CGH-design were 
evenly distributed across the rest of the genome with an 
average spacing of one probe per 25 kb. The CGH+SNP-
design comprised the same set (44,000) of gene-specific 
probes, ~60,000 SNP probes, and the remaining ~76,000 
oligonucleotides were the backbone probes covering the 
genome with an average of one probe per 40 kb. Both 
microarray designs had the average genomic resolution 
135–200 kb and an enhanced 5–10 kb resolution for 
targeted oncogenes and tumor suppressor genes. Detection 
of homozygous AA and BB and heterozygous AB alleles 
were performed by SNP genotyping of ~60,000 Alu/
Rsa site-containing oligonucleotide probes included on 
the Agilent CGH+SNP microarray. Long stretches of 
homozygosity (>20 Mb) which are unlikely to represent 
ancestral genomic regions, and are therefore not expected 
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to exist in the germlines of healthy individuals, were 
classified as acquired LOH segments. Microarray 
experiments and analyses were performed according to the 
manufacturer’s protocol. Detailed information is provided 
in the Supplementary Data.
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